Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 3

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 9481Neoplasms 6589Prostatic Neoplasms 4399Colorectal Neoplasms 3978Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Leukemia, Myeloid, Acute 2265Multiple Myeloma 2121Stomach Neoplasms 2109Neoplasm Metastasis 1911Head and Neck Neoplasms 1870Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1730Brain Neoplasms 1702Rectal Neoplasms 1676Melanoma 1656Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1486Esophageal Neoplasms 1312Glioblastoma 1308Lymphoma, Non-Hodgkin 1205Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

durvalumab 1Surgical Procedures, Operative 1Radiotherapy 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × SCLC, Limited Stage × Clear all
NCT07309211 2025-12-30

Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT

The First Affiliated Hospital with Nanjing Medical University

Recruiting
25 enrolled
Thoracic

SCLC, Limited Stage

NCT06911606 2025-04-04

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

Guangdong Provincial People's Hospital

Phase 2 Recruiting
45 enrolled
Thoracic

SCLC, Limited Stage

NCT06371482 2024-06-17

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Hebei Medical University Fourth Hospital

Phase 2 Recruiting
58 enrolled
Thoracic

SCLC, Limited Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡